Dimerix : Investor Call and Presentation

For personal use only

Immediate Release

DIMERIX INVESTOR CALL & PRESENTATION

MELBOURNE, Australia, 1 March 2022: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company invites shareholders to attend its investor webinar held today at 11am (AEDT) 1 March 2022.

The webinar will cover Dimerix' activities, including the announcement regarding the changes to the REMAP-CAPCOVID-19 study.

Interested parties can register for the webinar using this link: https://zoom.us/webinar/register/WN_q1mnHbYTStCIbQ_CIejUwg

An investor presentation is attached to this announcement. Participants may submit questions during registration or during the session.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster	Rudi Michelson
Dimerix Limited	Monsoon Communications
Chief Executive Officer & Managing Director	Tel: [phone]
Tel: [phone]	Mob: [phone]
E: [e-mail]	E: [e-mail]

Follow us on LinkedInand Twitter

Authorised for lodgement by the Board of the Company

-END-

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease1. DMX-200 is protected by granted patents in various territories until 2032, with additional applications submitted that may extend the protection to 2042 if granted.

DMX-200 has demonstrated encouraging data that could provide meaningful clinical outcomes for patients with kidney disease across 4 clinical studies to date1. DMX-200 is also under investigation as a potential treatment for patients with COVID-19 in two separate studies: REMAP-CAP and CLARITY 2.0.

References

1 ASX releases: 12Jul17, 18Oct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21

Dimerix is a biopharmaceutical	Dimerix HQ
425 Smith St, Fitzroy 3065
company developing innovative new	Victoria, Australia
therapies in areas with unmet	T. 1300 813 321
medical needs.	E. [e-mail]

ersonal use only

ersonal use only

ersonal use only

ersonal use only

Share price	Top shareholders